• ImmuPharma Completes Pivotal Phase 3 Trial of Its Lupus Therapy Lupuzor
  • 2017 Brought Notable Advances in Research and Awareness, Lupus Foundation Says
  • Most Cerebrovascular Events in Lupus Patients are Caused by Disease Itself, Study Shows
  • Rituxan Controls Disease Activity, Reduces Corticosteroid Use in Lupus Patients, Study Finds
  • Exploring Links Between PTSD, Trauma, and Lupus
  • Mixed Connective Tissue Disease Shows Milder Activity than Other Rheumatic Disorders, Study Finds
  • The Opposite of My New Year’s Resolution
  • Study Links Higher Body Mass Index and Obesity to Increased Fatigue Levels in Lupus Patients
  • Suppressing One Monster by Exposing Myself to Others
  • Benlysta Plus Standard of Care Improved Disease Activity in Phase 3 Northeast Asia Trial
  • SLE Patients with Pulmonary Arterial Hypertension Have ‘Relatively Good’ Survival Rates, Study Shows
  • Ra Pharmaceuticals Initiates Phase 1b Trial of New Therapy for Lupus Nephritis